You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Alembic Pharma rises after final USFDA nod for anti-infective gel

Capital Market 

Alembic Pharmaceuticals gained 1.12% to Rs 783.15 after the drug maker announced that its joint venture, Aleor Dermaceuticals, received final approval from the US drug regulator for metronidazole gel.

Metronidazole gel USP is indicated for the topical treatment of inflammatory lesions of rosacea.

Aleor had previously received tentative approval for this Abbreviated New Drug Application (ANDA). The approved ANDA is therapeutically equivalent to the reference listed drug product Metrogel Gel 1%, of Galderma Laboratories LP.

According to IQVIA, metronidazole gel USP has an estimated market size of $29 million for twelve months ending June 2021.

Alembic has a cumulative total of 149 ANDA approvals (132 final approvals and 17 tentative approvals) from USFDA.

Aleor is a 60:40 joint venture between Alembic and Orbicular Pharmaceutical Technologies formed in Apr 2016 focusing on commercialising dermatology products globally.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. The drug maker's consolidated net profit dropped 45.42% to Rs 164.52 crore on a 1.13% fall in revenue from operations to Rs 1,326.03 crore in Q1 FY22 over Q1 FY21.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 06 2021. 13:51 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU